北京鑫開元醫(yī)藥科技有限公司是國內(nèi)領(lǐng)先的一站式CRO服務(wù)平臺企業(yè)。主營業(yè)務(wù)涉及創(chuàng)新藥研發(fā)、改良型新藥研發(fā)、仿制藥研發(fā)、中藥臨床前研發(fā)以及MAH合作。

公司成立于2014年，發(fā)展至今已擁有 5 所研發(fā)中心，研發(fā)場地總面積達(dá) 20000 余平米，并在海南和上海各擁有一家臨床前研究所。

公司擁有全套藥品研發(fā)的標(biāo)準(zhǔn)設(shè)備 600 余臺，具備原料藥和制劑工藝開發(fā)及產(chǎn)業(yè)化、藥品質(zhì)量研究的研發(fā)體系及專業(yè)的項目管理體系，并已獲得 ISO9001 、ISO14001認(rèn)證，以及 CNAS 認(rèn)可。目前公司研發(fā)人員700余人，博士20余人。

Beijing Xinkaiyuan Pharmtech Co., Ltd is a leading pharmaceutical one-stop CRO service platform. The major business is R&D of innovative drugs, R&D of modified new drugs, R&D of generic drugs, R&D of traditional Chinese medicine and MAH cooperation. 

Xinkaiyuan was established in 2014 and has developed 5 R&D centers so far. It has more than 20,000 m2 of R&D laboratory internally, and each has a preclinical research institute in Shanghai and Hainan.

Currently, Xinkaiyuan has more than 600 sets of advanced instruments, and an advanced quality and project management system certificated by ISO-9001 ,ISO-14001 and CNAS. The company has more than 700 employees and more than 20 PhDs.